<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) comprise a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> collection of lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) is the second most common NHL sub-type </plain></SENT>
<SENT sid="2" pm="."><plain>Over the last years, the introduction of the anti-CD20 monoclonal antibody rituximab has radically changed treatment of FL </plain></SENT>
<SENT sid="3" pm="."><plain>After several large prospective randomized trials demonstrated prolongation of remission, current European indications for rituximab include the first-line treatment of patients with stage III-IV FL in combination with polychemotherapy such as CVP or CHOP </plain></SENT>
<SENT sid="4" pm="."><plain>This paper discusses the treatment of primary nodal FL with secondary cutaneous involvement with rituximab as monotherapy without additional chemotherapy </plain></SENT>
</text></document>